<ENAMEX TYPE="ORGANIZATION">Biogen Inc.</ENAMEX> said it signed a $20 million funding agreement with <ENAMEX TYPE="ORGANIZATION">New York Life Insurance Co.</ENAMEX> that will expand <ENAMEX TYPE="ORGANIZATION">Biogen</ENAMEX>'s development and commercialization efforts for products based on the experimental AIDS drug, CD-4.
Upon introduction into the marketplace of products based on CD-4, <ENAMEX TYPE="ORGANIZATION">New York Life</ENAMEX> would earn royalties on sales world-wide. In addition, <ENAMEX TYPE="ORGANIZATION">New York Life</ENAMEX> will receive warrants for 1.8 million shares of <ENAMEX TYPE="ORGANIZATION">Biogen</ENAMEX> common stock, exercisable at $17 a share between July 1992 and December 1996.
This is <ENAMEX TYPE="ORGANIZATION">New York Life</ENAMEX>'s second funding agreement with a pharmaceutical company for research and development of products to treat acquired immune deficiency syndrome. In May 1988, the insurance company reached an $8.5 million financing arrangement with <ENAMEX TYPE="ORGANIZATION">IDEC Pharmaceuticals Corp.</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">La Jolla</ENAMEX>, <ENAMEX TYPE="LOCATION">Calif.</ENAMEX>
In national over-the-counter trading, common of <ENAMEX TYPE="ORGANIZATION">Biogen</ENAMEX>, a <ENAMEX TYPE="LOCATION">Cambridge</ENAMEX>, <ENAMEX TYPE="LOCATION">Mass.</ENAMEX>, biotechnology company, fell 37.5 cents to close at $12.125 a share.
